Besides the anti-fungal agent cercosporamide, which was identified as an MNK1/2 inhibitor reducing CRC cell viability as well as growth of CRC xenografts [148], the more specific MNK1/2 inhibitor eFT508 was identified through structure-based design [149]. The gene discussed is MKNK1; the disease is colorectal carcinoma.